Success Metrics

Clinical Success Rate
90.2%

Based on 101 completed trials

Completion Rate
90%(101/112)
Active Trials
13(8%)
Results Posted
40%(40 trials)
Terminated
11(7%)

Phase Distribution

Ph phase_4
57
34%
Ph not_applicable
25
15%
Ph phase_2
39
23%
Ph early_phase_1
1
1%
Ph phase_3
26
15%
Ph phase_1
15
9%

Phase Distribution

16

Early Stage

39

Mid Stage

83

Late Stage

Phase Distribution163 total trials
Early Phase 1First-in-human
1(0.6%)
Phase 1Safety & dosage
15(9.2%)
Phase 2Efficacy & side effects
39(23.9%)
Phase 3Large-scale testing
26(16.0%)
Phase 4Post-market surveillance
57(35.0%)
N/ANon-phased studies
25(15.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

87.1%

101 of 116 finished

Non-Completion Rate

12.9%

15 ended early

Currently Active

13

trials recruiting

Total Trials

168

all time

Status Distribution
Active(21)
Completed(101)
Terminated(15)
Other(31)

Detailed Status

Completed101
unknown31
Recruiting12
Terminated11
Not yet recruiting7
Withdrawn4

Development Timeline

Analytics

Development Status

Total Trials
168
Active
13
Success Rate
90.2%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (0.6%)
Phase 115 (9.2%)
Phase 239 (23.9%)
Phase 326 (16.0%)
Phase 457 (35.0%)
N/A25 (15.3%)

Trials by Status

terminated117%
active_not_recruiting11%
completed10160%
enrolling_by_invitation11%
unknown3118%
not_yet_recruiting74%
recruiting127%
withdrawn42%

Recent Activity

Clinical Trials (168)

Showing 20 of 168 trialsScroll for more
NCT01275560Phase 3

Does the Negativation of the Glucose Hydrogen Breath Test Come Along With a Reduction of the Symptoms of Gaz Incontinence ?

Completed
NCT06569368Phase 2

Trial Utilizing Metronidazole to Optimize the Microbiome of Rectal Adenocarcinoma Undergoing Neoadjuvant Therapy

Recruiting
NCT06131021Phase 3

Shaping the Indications for Periodontal Adjunctive Antibiotics in Dental Practice

Completed
NCT07492134Phase 2

APLAUD Trial (Antibiotics vs PLacebo for Acute Uncomplicated Diverticulitis)

Not Yet Recruiting
NCT07451171Phase 2

Comparative Efficacy of Antibiotics for Small Intestine Bacterial Overgrowth in Bangladeshi Children

Not Yet Recruiting
NCT06627270Phase 2

Antibiotic Treatment Effects on Intratumoral Bacteria Modulation in Surgical Patients With Oral Cancer

Recruiting
NCT06616597Phase 2

Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer

Recruiting
NCT01722708Not Applicable

Comparison Between Oral Clindamycin Vs Metronidazole for the Treatment of Abnormal Vaginal Flora in High Risk Pregnancies

Completed
NCT04729322Phase 2

Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders

Active Not Recruiting
NCT05926804Not Applicable

A "Screen and Treat" Helicobacter Pylori Eradication Trial in Adolescents in Three Regions of Chile

Recruiting
NCT07180615Phase 4

Gut Decolonisation With Neomycin/Metronidazole or Rifaximin Before Colon Surgery

Not Yet Recruiting
NCT06806995Phase 1

A Single-center, Open-label, Study Evaluating Safety and Pharmacokinetics of Single Doses of Zidebactam-Cefepime and Metronidazole Alone or in Combination.

Completed
NCT05874544Phase 4

Rescue Therapy for Helicobacter Pylori Infection

Completed
NCT07086937Not Applicable

Efficacy of Nitazoxanide Based Therapy vs Standard Triple Therapy in H-pylori in Children

Completed
NCT04186247Phase 2

Personalized AZithromycin/metronidAZole Therapy in Pediatric Crohn's Disease (CD)

Terminated
NCT06387147Phase 3

ORal Antibiotics in Acute Mesenteric Ischemia

Recruiting
NCT06798415Phase 2

Intralesional Injection of Metronidazole for the Management of Cutaneous Leishmaniasis

Recruiting
NCT06793137Phase 2

Intestinal Microbiome Modulation With Antibiotics in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer

Recruiting
NCT05874570Phase 4

Doxycycline for Helicobacter Pylori Rescue Treatment

Recruiting
NCT06731023

Efficacy of a 14-Day Bismuth-Containing Quadruple Therapy Guided by Drug Susceptibility Testing in Patients with Extremely Refractory Helicobacter Pylori Infection: an Exploratory Study

Not Yet Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
168